Bernstein analyst Lance Wilkes lowered the firm’s price target on CVS Health (CVS) to $93 from $107 and keeps a Market Perform rating on the shares. The firm notes CVS is reporting Q1 results this Wednesday but that this "isn’t a call on Q1 earnings," as it thinks CVS PBM operating results could be solid in the quarter. PBM policy risk has come into sharp focus, with multiple Congressional Committees investigating PBMs. This has led to a challenging stock price year with Cigna (CI) and CVS down 20% year-to-date. The underperformance is driven by increased scrutiny on PBM business practices, and potential legislative and regulatory actions that could pressure bottom line, Bernstein adds. The firm sees a potential margin risk to PBMs and expects valuations will remain compressed for PBMs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CVS:
- CVS HEALTH REPORTS FIRST QUARTER RESULTS, COMPLETES ACQUISITIONS OF SIGNIFY HEALTH AND OAK STREET HEALTH
- CVS Health completes acquisition of Oak Street Health
- Cigna price target lowered to $293 from $367 at Bernstein
- CVS Health initiated with an Overweight at Cantor Fitzgerald
- CVS Health division enters collaboration with Catholic Health